StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$22.93−0.21 (-0.91%)

Close on Nov 19, 2026Market cap $458.86MP/E –Yield –

Neurogene net income

Net income is the profit left for shareholders after every expense, interest and tax.

Neurogene's net income for the twelve months ending Jun 30, 2026 was -$111.11M. For fiscal 2025 it was -$90.35M. The highest annual figure on record is -$7.71M in fiscal 2012.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$90.35M–
FY2024Dec 31, 2024-$75.14M–
FY2023Dec 31, 2023-$36.32M–
FY2022Dec 31, 2022-$55.19M–
FY2021Dec 31, 2021-$60.69M–
FY2020Dec 31, 2020-$33.28M–
FY2019Dec 31, 2019-$69.44M–
FY2018Dec 31, 2018-$31.59M–
FY2017Dec 31, 2017-$50.18M–
FY2016Dec 31, 2016-$37.00M–
FY2015Dec 31, 2015-$21.86M–
FY2014Dec 31, 2014-$24.03M–
FY2013Dec 31, 2013-$8.73M–
FY2012Dec 31, 2012-$7.71M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$34.49M–
Q1 FY2026Mar 31, 2026-$30.93M–
Q4 FY2025Dec 31, 2025-$24.74M–
Q3 FY2025Sep 30, 2025-$20.95M–
Q2 FY2025Jun 30, 2025-$22.02M–
Q1 FY2025Mar 31, 2025-$22.65M–
Q4 FY2024Dec 31, 2024-$19.51M-918.9%
Q3 FY2024Sep 30, 2024-$20.22M–
Q2 FY2024Jun 30, 2024-$18.49M–
Q1 FY2024Mar 31, 2024-$16.92M–
Q4 FY2023Dec 31, 2023$2.38M–
Q3 FY2023Sep 30, 2023-$14.58M–
Q2 FY2023Jun 30, 2023-$11.86M–
Q1 FY2023Mar 31, 2023-$12.26M–
Q4 FY2022Dec 31, 2022-$11.08M–
Q3 FY2022Sep 30, 2022-$13.07M–
Q2 FY2022Jun 30, 2022-$15.69M–
Q1 FY2022Mar 31, 2022-$15.35M–
Q4 FY2021Dec 31, 2021-$15.17M–
Q3 FY2021Sep 30, 2021-$15.45M–
Q2 FY2021Jun 30, 2021-$15.13M–
Q1 FY2021Mar 31, 2021-$14.95M–
Q4 FY2020Dec 31, 2020-$12.64M–
Q3 FY2020Sep 30, 2020-$2.25M–
Q2 FY2020Jun 30, 2020-$9.75M–
Q1 FY2020Mar 31, 2020-$8.64M–
Q4 FY2019Dec 31, 2019-$8.10M–
Q3 FY2019Sep 30, 2019-$59.13M–
Q2 FY2019Jun 30, 2019-$1.00K-100.0%
Q1 FY2019Mar 31, 2019-$2.21M–
Q4 FY2018Dec 31, 2018-$4.89M–
Q3 FY2018Sep 30, 2018-$14.99M–
Q2 FY2018Jun 30, 2018$2.92M–
Q1 FY2018Mar 31, 2018-$14.62M–
Q4 FY2017Dec 31, 2017-$16.27M–
Q3 FY2017Sep 30, 2017-$11.83M–
Q2 FY2017Jun 30, 2017-$13.77M–
Q1 FY2017Mar 31, 2017-$8.32M–
Q4 FY2016Dec 31, 2016-$11.24M–
Q3 FY2016Sep 30, 2016-$8.15M–

More Neurogene figures

See a number that looks wrong?